Home » Topics » BioWorld Science

BioWorld Science
RSS

Ovid licenses KCC2 transporter activators from AstraZeneca

Jan. 4, 2022

Novel allosteric inhibitor of tumor-promoting PPI between AIMP2-DX2 and HSP70

Jan. 4, 2022

uPA-uPAR blockade protects intestinal epithelial barrier from inflammation-induced damage

Jan. 4, 2022

Discovery of triple-action inhibitor for the treatment of neurodegenerative diseases

Jan. 4, 2022

Arbutus Biopharma presents new HBV and/or HDV capsid assembly inhibitors

Jan. 4, 2022

Roche identifies new ENPP2 inhibitors

Jan. 4, 2022

Chinese researchers synthesize new SOS1 inhibitors

Jan. 4, 2022

Leo Pharma patents IL-17 modulators

Jan. 4, 2022

Medshine Discovery discloses EZH2 inhibitors

Jan. 4, 2022

Novel inhibitors of fungal FA biosynthesis show broad-spectrum antifungal activity

Jan. 4, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...